R&G PharmaStudies Co., Ltd. reported earnings results for the nine months ended September 30, 2023. For the nine months, the company reported sales was CNY 524.67 million compared to CNY 468.19 million a year ago. Revenue was CNY 524.67 million compared to CNY 468.19 million a year ago.

Net income was CNY 125.86 million compared to CNY 83.84 million a year ago. Basic earnings per share from continuing operations was CNY 1.31 compared to CNY 1.08 a year ago. Diluted earnings per share from continuing operations was CNY 1.31 compared to CNY 1.08 a year ago.